Format

Send to

Choose Destination
Odontology. 2015 Sep;103(3):258-63. doi: 10.1007/s10266-015-0195-4. Epub 2015 Feb 6.

Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.

Author information

1
Department of Neurosciences, Institute of Clinical Dentistry, University of Padova, Via Venezia 90, 35129, Padua, Italy.
2
Department of Neurosciences, Institute of Clinical Dentistry, University of Padova, Via Venezia 90, 35129, Padua, Italy. marleen.debiagi@gmail.com.
3
DDS, Resident, Institute of Clinical Dentistry, Azienda Ospedaliera, University of Padova, Via Venezia 90, 35129, Padua, Italy. marleen.debiagi@gmail.com.
4
Department of Cardiac Thoracic and Vascular Sciences, Padova University Hospital, Via Giustiniani 2, 35128, Padua, Italy.

Abstract

The development of new orally administered anticoagulants, such as dabigatran, rivaroxaban, and apixaban, in the past few years has focused on avoiding some of the drawbacks associated with warfarin. This work aims to illustrate the main features of the most commonly used new oral anticoagulants, reviewing the current literature on the management of patients taking these drugs and needing oral and implant surgery, and discussing the currently proposed related guidelines.

KEYWORDS:

Apixaban; Dabigatran; Oral anticoagulants; Oral surgery; Rivaroxaban

PMID:
25656043
DOI:
10.1007/s10266-015-0195-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center